Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆Xiaohua Wu, Mansoor Raza Mirza, Rutie Yin et al.|Annals of Oncology|2021Cited by 212